Assignee
REGENXBIO INC
US·6 granted patents·69 pending applications·2 citations·filing 2017–2025
Top patents by PatentIndex Score
75 records- 0178US11986515B2Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)REGENXBIO INC·Filed 2023·Granted May 21, 2024·1 cites·30 claims
- 0276US2025367326A1Microdystrophin nucleic acid gene therapy constructs and uses thereofREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0376US2025367328A1Methods of manufacturing microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0476US2025367327A1Treatment of dystrophinopathies with microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0572US2024254214A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0671US11613739B2Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cellsREGENXBIO INC·Filed 2018·Granted Mar 28, 2023·1 cites·16 claims
- 0770US2025312492A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0867US2025051740A1Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cellsREGENXBIO INC·Filed 2024·Application pending·0 cites
- 0966US2023057519A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1066US2025186904A1Anion exchange chromatography for recombinant aav productionREGENXBIO INC·Filed 2024·Application pending·0 cites
- 1165US2024216543A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1265US2025249127A1Gene therapy for treating an ocular diseaseREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1365US2025215401A1Compositions and methods for recombinant aav productionREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1464US2025320287A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2025·Application pending·0 cites
- 1563US2023270886A1Microdystrophin gene therapy constructs and uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1663US2024050537A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2023·Application pending·0 cites
- 1763US2025230465A1Compositions and methods for recombinant aav productionREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1861US2025277004A1Hybrid aav capsidsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1961US2026055144A1Recombinant adeno-associated viruses and uses thereofREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2060US2025213727A1Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapyREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2160US2025288697A1Vectorized anti-tnf-alpha inhibitors for ocular indicationsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2259US2026034246A1Vectorized anti-complement antibodies and complement agents and administration thereofREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2359US2025207126A1Modified muscle-specific promotersREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2458US2024167054A1Method of producing a recombinant virus particleREGENXBIO INC·Filed 2021·Application pending·0 cites
- 2558US2024358857A1Treatment of duchenne muscular dystrophy and combinations thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 2658US2026042993A1Scalable clarification process for recombinant aav productionREGENXBIO INC·Filed 2025·Application pending·0 cites
- 2757US2025276097A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 2857US2026034243A1Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administrationREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2957US2023390418A1Vectorized factor xii antibodies and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3056US2025001006A1Recombinant adeno-associated viruses for targeted deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 3156US2024384292A1Vectorized tnf-alpha antagonists for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3256US2024309076A1Tau-specific antibody gene therapy compositions, methods and uses thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3356US2019211091A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2019·Application pending·0 cites
- 3455US2025179518A1Recombinant adeno-associated viruses for cns tropic deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 3555US2020277364A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2018·Application pending·0 cites
- 3655US2024425572A1Antibodies and methods of using thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 3754US12070702B2Anion exchange chromatography for recombinant AAV productionREGENXBIO INC·Filed 2019·Granted Aug 27, 2024·0 cites·13 claims
- 3854US2024117328A1Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)REGENXBIO INC·Filed 2022·Application pending·0 cites
- 3954US2024218397A1Novel aav vectors and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 4053US2023381341A1Adeno-associated viruses for ocular delivery of gene therapyREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4152US2025339555A1Formulations for suprachoroidal administration such as formulations with aggregate formationREGENXBIO INC·Filed 2023·Application pending·0 cites
- 4252US2025326861A1Vectorized lanadelumab and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4351US2023374541A1Recombinant adeno-associated viruses for cns or muscle deliveryREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4450US2025025574A1Engineered nucleic acid regulatory elements and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 4550US2019127455A1Treatment of Ocular Diseases with Fully- Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2017·Application pending·0 cites
- 4650US2021324483A1Method for measuring the infectivity of replication defective viral vectors and virusesREGENXBIO INC·Filed 2019·Application pending·0 cites
- 4750US2024124890A1Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4850US2023391864A1Vectorized anti-tnf-alpha antibodies for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4949US12365865B2Scalable clarification process for recombinant AAV productionREGENXBIO INC·Filed 2019·Granted Jul 22, 2025·0 cites·17 claims
- 5049US2026034250A1Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fabREGENXBIO INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →